IGF2BP3

Across TCGA pan-cancer cohorts, IGF2BP3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IGF2BP3 data layer compared with 28 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher IGF2BP3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGF2BP3 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

SCLC, SARC, and UCEC are the cancer types where IGF2BP3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Median	All	0.219	0.636	.007	15	view →
SARC	DFS	Median	All	0.107	0.613	<.001	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	OS	Median	All	0.105	0.774	.002	3	view →
SKCM	DFS	Median	II,III,IV	0.876	0.546	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

IGF2BP3–SCLC (DFS)

Open the SCLC breakdown →